Simultaneous and accurate measurement of the dielectric constant at many frequencies spanning a wide range

We present an innovative technique which allows the simultaneous measurement of the dielectric constant of a material at many frequencies, spanning a four orders of magnitude range chosen between 10 --2 Hz and 10 4 Hz. The sensitivity and accuracy are comparable to those obtained using standard single frequency techniques. The technique is based on three new and simple features: a) the precise real time correction of the amplication of a current amplier; b) the specic shape of the excitation signal and its frequency spectrum; and c) the precise synchronization between the generation of the excitation signal and the acquisition of the dielectric response signal. This technique is useful in the case of relatively fast dynamical measurements when the knowledge of the time evolution of the dielectric constant is needed

New insights in sources of the sub-micrometre aerosol at Mt. Zeppelin observatory (Spitsbergen) in the year 2015

In order to evaluate the potential impact of the Arctic anthropogenic emission sources it is essential to understand better the natural aerosol sources of the inner Arctic and the atmospheric processing of the aerosols during their transport in the Arctic atmosphere. A 1-year time series of chemically specific measurements of the sub-micrometre aerosol during 2015 has been taken at the Mt. Zeppelin observatory in the European Arctic. A source apportionment study combined measured molecular tracers as source markers, positive matrix factorization, analysis of the potential source distribution and auxiliary information from satellite data and ground-based observations. The annual average sub-micrometre mass was apportioned to regional background secondary sulphate (56%), sea spray (17%), biomass burning (15%), secondary nitrate (5.8%), secondary marine biogenic (4.5%), mixed combustion (1.6%), and two types of marine gel sources (together 0.7%). Secondary nitrate aerosol mainly contributed towards the end of summer and during autumn. During spring and summer, the secondary marine biogenic factor reached a contribution of up to 50% in some samples. The most likely origin of the mixed combustion source is due to oil and gas extraction activities in Eastern Siberia. The two marine polymer gel sources predominantly occurred in autumn and winter. The small contribution of the marine gel sources at Mt. Zeppelin observatory in summer as opposed to regions closer to the North Pole is attributed to differences in ocean biology, vertical distribution of phytoplankton, and the earlier start of the summer season

Dynamique moléculaire et plasticité d'un polymère amorphe sous traction

L'amélioration des performances des matériaux polymères passent notamment par une meilleure compression du lien entre dynamiques moléculaires à l'échelle microscopique et propriétés mécaniques macroscopiques. Dans ce but, la mobilité des chaînes polymères a été sondée par une mesure de spectroscopie diélectrique lors de la déformation plastique d'un polymère vitreux

Towards establishment of a centralized spider traits database

A main goal of ecological and evolutionary biology is understanding and predicting interactions between populations and both abiotic and biotic environments, the spatial and temporal variation of these interactions, and the effects on population dynamics and performance. Trait-based approaches can help to model these interactions and generate a comprehensive understanding of ecosystem functioning. A central tool is the collation of databases that include species trait information. Such centralized databases have been set up for a number of organismal groups but is lacking for one of the most important groups of predators in terrestrial ecosystems - spiders. Here we promote the collation of an open spider traits database, integrated into the global Open Traits Network. We explore the current collation of spider data and cover the logistics of setting up a global database, including which traits to include, the source of data, how to input data, database governance, geographic cover, accessibility, quality control and how to make the database sustainable long-term. Finally, we explore the scope of research questions that could be investigated using a global spider traits database.Peer reviewe

The impact from survey depth and resolution on the morphological classification of galaxies

We consistently analyse for the first time the impact of survey depth and spatial resolution on the most used morphological parameters for classifying galaxies through non-parametric methods: Abraham and Conselice-Bershady concentration indices, Gini, M20moment of light, asymmetry, and smoothness. Three different non-local data sets are used, Advanced Large Homogeneous Area Medium Band Redshift Astronomical (ALHAMBRA) and Subaru/XMMNewton Deep Survey (SXDS, examples of deep ground-based surveys), and Cosmos Evolution Survey (COSMOS, deep space-based survey). We used a sample of 3000 local, visually classified galaxies, measuring their morphological parameters at their real redshifts (z ~ 0). Then we simulated them to match the redshift and magnitude distributions of galaxies in the non-local surveys. The comparisons of the two sets allow us to put constraints on the use of each parameter for morphological classification and evaluate the effectiveness of the commonly used morphological diagnostic diagrams. All analysed parameters suffer from biases related to spatial resolution and depth, the impact of the former being much stronger. When including asymmetry and smoothness in classification diagrams, the noise effects must be taken into account carefully, especially for ground-based surveys. M20 is significantly affected, changing both the shape and range of its distribution at all brightness levels. We suggest that diagnostic diagrams based on 2-3 parameters should be avoided when classifying galaxies in ground-based surveys, independently of their brightness; for COSMOS they should be avoided for galaxies fainter than F814 = 23.0. These results can be applied directly to surveys similar to ALHAMBRA, SXDS and COSMOS, and also can serve as an upper/lower limit for shallower/deeper ones.Ministerio de Economía y Competitividad AYA2010-15169, AYA2013-42227-P, AYA2013-4318

Accumulation of Polychlorinated Biphenyls in Adipocytes: Selective Targeting to Lipid Droplets and Role of Caveolin-1

Background : Polychlorinated biphenyls (PCBs) are persistent environmental pollutants that preferentially accumulate in lipid-rich tissues of contaminated organisms. Although the adipose tissue constitutes a major intern reservoir of PCBs and recent epidemiological studies associate PCBs to the development of obesity and its related disorders, little is known about the mechanisms involved in their uptake by the adipose tissue and their intracellular localization in fat cells

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

Table S2. Spearman correlation of the expression of four glycolytic enzymes in a cohort of 380 ovarian cancers. Spearman rho correlation values (top value) along with the respective adjusted P value (bottom value) of statistically significant correlations thresholded at FDR P < 0.01 are summarised. (DOCX 21 kb

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence. Objective: To present the voting results of the APCCC 2022. Design, setting, and participants: The experts voted on controversial questions where high- level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration- resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions. Outcome measurements and statistical analysis: The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration- resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions. Results and limitations: The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer. Conclusions: These voting results in four specific areas from a panel of experts in advanced prostate cancer can help clinicians and patients navigate controversial areas of management for which high-level evidence is scant or conflicting and can help research funders and policy makers identify information gaps and consider what areas to explore further. However, diagnostic and treatment decisions always have to be individualised based on patient characteristics, including the extent and location of disease, prior treatment(s), co-morbidities, patient preferences, and treatment recommendations and should also incorporate current and emerging clinical evidence and logistic and economic factors. Enrolment in clinical trials is strongly encouraged. Importantly, APCCC 2022 once again identified important gaps where there is non-consensus and that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with healthcare providers worldwide. At each APCCC, an expert panel votes on pre-defined questions that target the most clinically relevant areas of advanced prostate cancer treatment for which there are gaps in knowledge. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients and their relatives as part of shared and multidisciplinary decision-making. This report focuses on the advanced setting, covering metastatic hormone-sensitive prostate cancer and both non-metastatic and metastatic castration-resistant prostate cancer. Twitter summary: Report of the results of APCCC 2022 for the following topics: mHSPC, nmCRPC, mCRPC, and oligometastatic prostate cancer. Take-home message: At APCCC 2022, clinically important questions in the management of advanced prostate cancer management were identified and discussed, and experts voted on pre-defined consensus questions. The report of the results for metastatic and/or castration- resistant prostate cancer is summarised here

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life